By
Pharmaceutical Co., Ltd.
Published: April 2, 2013, 10:09 p.m.·
Tags:
None
-- Delamanid, discovered and developed by Otsuka, has been filed in Japan for the treatment of multidrug-resistant tuberculosis (MDR-TB), following the application in Europe in 2011. This is the first drug application in Japan seeking an indication for treatment of MDR-TB.
-- According to WHO, tuberculosis is one of the three most common infectious diseases. Every year, approximately 8.7 million people become sick, and nearly 1.4 million people die from TB or TB-related causes. It is estimated that 440,000 new cases of MDR-TB emerge each year, leading to 150,000 deaths annually.
-- Otsuka has been working in the TB field for more than 40 years and in 2011 was recognized as the world’s lead investor in TB drug development.i Otsuka is driven by the dream to create a novel drug for tuberculosis.
Read More →